Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate tablets are indicated in:  - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.  sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

chartwell rx, llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate tablets are indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients. safety and effectiveness in pediatric patients have not been established. clinical studies of sucralfate tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, r

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

atlantic biologicals corp. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

pinnacle pharma llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oralsuspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oralsuspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

zydus lifesciences limited - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate tablets are indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

viona pharmaceuticals inc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate tablets are indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate is indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate is contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate is indicated in: sucralfate is contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate is indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate is contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate tablets are indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.